Am J Psychiatry 157:767-771, May 2000
© 2000 American Psychiatric Association
Normal P50 Suppression in Schizophrenia Patients Treated With Atypical Antipsychotic Medications
Gregory A. Light, B.A.,
Mark A. Geyer, Ph.D.,
Brett A. Clementz, Ph.D.,
Kristin S. Cadenhead, M.D., and
David L. Braff, M.D.
ABSTRACT
OBJECTIVE: Patients with schizophrenia have deficits in attention, cognition, and information processing. Measures such as P50 suppression are used to study cognitive and attentional dysfunction among these patients. P50 suppression is an operational measure of sensory gating that can be assessed by averaging electroencephalographic responses to multiple pairs of auditory clicks separated by 500 msec. Normally, the P50 response to the second click is smaller than the response to the first click. Many studies have demonstrated that schizophrenia patients have deficient P50 suppression, meaning that the difference between the first and second clicks is not as large as normal. Atypical antipsychotic medications may have superior clinical efficacy for negative symptoms and cognitive deficits. It is important, therefore, to evaluate the effects of atypical antipsychotic medications on measures such as P50 suppression. METHOD: P50 suppression of 13 patients with schizophrenia receiving clinically effective doses of clozapine, olanzapine, or risperidone (classified as atypical antipsychotic medications) was compared to that of 13 patients receiving conventional antipsychotic medications. RESULTS: The patient groups did not differ on clinical or demographic measures. The patients receiving atypical antipsychotic medications had normal-range P50 suppression (mean=72%). In contrast, the patients receiving typical antipsychotic medications had dramatically lower P50 suppression (mean=27%). CONCLUSIONS: The results support the hypothesis that patients treated with atypical antipsychotic medications have normal P50 measures of sensory gating. Longitudinal within-subjects studies are warranted to clarify the mechanisms mediating this effect.
This article has been cited by other articles:
|
|
|
|
 
T. A. Greenwood, D. L. Braff, G. A. Light, K. S. Cadenhead, M. E. Calkins, D. J. Dobie, R. Freedman, M. F. Green, R. E. Gur, R. C. Gur, et al.
Initial Heritability Analyses of Endophenotypic Measures for Schizophrenia: The Consortium on the Genetics of Schizophrenia
Arch Gen Psychiatry,
November 1, 2007;
64(11):
1242 - 1250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. de Wilde, L. J. Bour, P. M. Dingemans, J. H. T. M. Koelman, and D. H. Linszen
Failure to Find P50 Suppression Deficits in Young First-Episode Patients With Schizophrenia and Clinically Unaffected Siblings
Schizophr Bull,
November 1, 2007;
33(6):
1319 - 1323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Braff, R. Freedman, N. J. Schork, and I. I. Gottesman
Deconstructing Schizophrenia: An Overview of the Use of Endophenotypes in Order to Understand a Complex Disorder
Schizophr Bull,
January 1, 2007;
33(1):
21 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. I. Turetsky, M. E. Calkins, G. A. Light, A. Olincy, A. D. Radant, and N. R. Swerdlow
Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Schizophr Bull,
January 1, 2007;
33(1):
69 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Potter, A. Summerfelt, J. Gold, and R. W. Buchanan
Review of Clinical Correlates of P50 Sensory Gating Abnormalities in Patients with Schizophrenia
Schizophr Bull,
October 1, 2006;
32(4):
692 - 700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Louchart-de la Chapelle, I. Nkam, E. Houy, A. Belmont, J.-F. Menard, A.-C. Roussignol, O. Siwek, M. Mezerai, M. Guillermou, G. Fouldrin, et al.
A Concordance Study of Three Electrophysiological Measures in Schizophrenia
Am J Psychiatry,
March 1, 2005;
162(3):
466 - 474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Adler, A. Olincy, E. M. Cawthra, K. A. McRae, J. G. Harris, H. T. Nagamoto, M. C. Waldo, M.-H. Hall, A. Bowles, L. Woodward, et al.
Varied Effects of Atypical Neuroleptics on P50 Auditory Gating in Schizophrenia Patients
Am J Psychiatry,
October 1, 2004;
161(10):
1822 - 1828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Oranje, C. C. Gispen-de Wied, H. G. M. Westenberg, C. Kemner, M. N. Verbaten, and R. S. Kahn
Increasing Dopaminergic Activity: Effects of L-Dopa and Bromocriptine on Human Sensory Gating
J Psychopharmacol,
September 1, 2004;
18(3):
388 - 394.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Arango, A. Summerfelt, and R. W. Buchanan
Olanzapine Effects on Auditory Sensory Gating in Schizophrenia
Am J Psychiatry,
November 1, 2003;
160(11):
2066 - 2068.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Thoma, F. M. Hanlon, S. N. Moses, J. C. Edgar, M. Huang, M. P. Weisend, J. Irwin, A. Sherwood, K. Paulson, J. Bustillo, et al.
Lateralization of Auditory Sensory Gating and Neuropsychological Dysfunction in Schizophrenia
Am J Psychiatry,
September 1, 2003;
160(9):
1595 - 1605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Myles-Worsley
P50 Sensory Gating in Multiplex Schizophrenia Families From a Pacific Island Isolate
Am J Psychiatry,
December 1, 2002;
159(12):
2007 - 2012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. J. Daskalakis, B. K. Christensen, R. Chen, P. B. Fitzgerald, R. B. Zipursky, and S. Kapur
Evidence for Impaired Cortical Inhibition in Schizophrenia Using Transcranial Magnetic Stimulation
Arch Gen Psychiatry,
April 1, 2002;
59(4):
347 - 354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Light and D. L. Braff
Measuring P50 Suppression and Prepulse Inhibition in a Single Recording Session
Am J Psychiatry,
December 1, 2001;
158(12):
2066 - 2068.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2000
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
